# 1. Financial Performance ## A. Key Figures * **Consolidated Sales:** **₹899 Cr** (Dec 2025 quarter) (+28% YoY) * **EBITDA:** **₹103 Cr** (Dec 2025 quarter) (+19% YoY) · **₹86 Cr** (Dec 2024 quarter) * **Net Debt:** **₹1,215 Cr** (Dec 2025) · **₹1,234 Cr** (Sept 2025) * Debt/EBITDA: 2.8x (Dec 2025) ## B. Revenue Growth * **Volume-Led Expansion:** Strong top-line growth driven by **29% higher sales volume**, primarily from ramp-up of new capacities. ## C. EBITDA & Margins * **Margin Tailwinds:** EBITDA growth supported by improved specialty chemical margins and favorable product mix, despite **₹19 Cr in adverse impacts** from tariffs, downtime, and non-recurring charges. * **BOPET Margin Recovery:** Gross margin per kg doubled sequentially to **₹12/kg** on reduced Chinese imports and firmer demand, marking a significant turnaround. * **BOPP Margin Resilience:** Margins improved to **₹15–16/kg** amid seasonal softness, with management signaling near-term stability despite industry capacity additions. * **Cost Optimization:** Renewable power initiatives are already lowering input costs, with **material savings expected by FY28** from solar plant rollout. ## D. Net Debt & Leverage * **Deleveraging Underway:** Net debt reduced by ₹20 Cr in the quarter, with a clear path to meaningful reduction over the next **2–3 years** as capex yields returns. * **Favorable Debt Profile:** Weighted average cost of debt between **5% and 8%**, with potential benefit from recent RBI rate cuts yet to fully flow through. --- # 2. Product & Segment Performance ## A. Key Figures * **Specialty Chemical Sales:** **₹52 Cr** in Q3 FY26 (25% EBITDA margin) * **BOPP Gross Margin:** **₹13/kg** in Dec 2025 (↓ from ₹22/kg in Sept 2025) * **BOPET Gross Margin:** **₹12/kg** in Dec 2025 (↑ from ₹6/kg in Sept 2025) * **Zigly Topline Growth:** **>50% YoY** in Q3 FY26 * **Window Films Sales Run Rate:** **₹30 Cr annualized** ## B. Specialty Business * **Strategic Diversification:** Company has successfully reduced reliance on single business, now spanning Specialty, BOPET, and CPP segments, with targeted expansion into **new high-margin businesses** for improved ROCE stability. * **Core Segment Resilience:** Specialty business remains dominant at **60% of total revenue**, with strategic intent to grow to 75%, supported by innovation pipeline of **3 new products** nearing commercialization. * **Export Shield:** Specialty BOPP segment benefits from international focus, insulating it from domestic overcapacity risks. * **ROCE Enhancement:** New ventures in specialty chemicals and consumer segments are scaling and contributing to incremental ROCE, aligning with long-term value creation goals. ## C. BOPP & BOPET Films * **Margin Volatility:** BOPP margins faced sharp contraction in Q3 due to import surge, though recent improvement in December and January signals recovery momentum. * **BOPET Recovery:** BOPET margins more than doubled QoQ to ₹12/kg amid operational recovery, though still below prior-year levels, indicating partial normalization. * **Rigid Packaging Milestone:** Cosmo Plastech reached EBITDA breakeven in Dec 2025, operating at ~70% capacity, with profitability path tied to utilization and efficiency gains. ## D. Consumer & Zigly * **High-Growth Consumer Platform:** Consumer business—including Sunshield Films and window films—is scaling rapidly, achieving **₹30 Cr annualized sales**, with improving contribution margins and a strategic focus on Europe. * **Zigly Momentum & Strategic Exit:** Petcare segment delivered **over 50% YoY growth**, driven by high-margin services and house brands, and has built a valuable brand in a high-multiple sector; demerger remains on track for FY '27. * **Aggressive Scaling:** Consumer verticals are prioritizing product development, branding, and geographic expansion, with management setting aggressive targets for profitability at scale. --- # 3. Capacity & Utilization ## A. Key Figures * **Utilization Progress:** New line ran at **70%** in Q3, reached **~80%** by January, targeting **100% from March** * **Current Utilization:** **70%** overall, targeting **90%** on new lines next fiscal * **Output Potential:** **25–30%** higher output possible from BOPP/CPP lines via utilization gains ## B. New Line Ramp-Up * **Capex Cycle Complete:** Strategic investment phase concluded; focus now fully on **full capacity utilization** and scaling the **specialty film business**. * **Phased Ramp-Up Underway:** New 81,000-ton line ramping progressively due to supplier-led speed calibration, not demand constraints, with **full run-rate expected from March**. * **Product Transition Path:** New lines begin with core films, gradually shifting to **higher-margin specialty films** over time, enhancing return profile. * **Existing Lines Fully Utilized:** Old capacity already operating at **full utilization**, underscoring strong underlying demand. ## C. Utilization Targets * **Multi-Year Utilization Focus:** Management prioritizing **asset optimization over new Capex** for 3–4 years to drive margin expansion. * **Confidence in BOPP/BOPET Absorption:** Despite competitive pressures, expects **full utilization of BOPP and BOPET lines**, with global BOPP market to remain balanced. * **India Market Outlook:** Domestic flexible packaging market to be **largely balanced in FY '27**, but may face **supply-demand imbalance in FY '28**. * **CPP Lags in Ramp-Up:** Newer CPP business growing well but requires **additional 12 months** to reach full utilization. ## D. Output Potential * **Significant Hidden Capacity:** BOPP and CPP lines offer **25–30% output uplift potential** from current levels through better utilization and optimal product mix. * **Technical Utilization Ceiling:** “Possible utilization” accounts for micron and mix variability; **BOPP and BOPET lines expected to hit full technical capacity**, while CPP lags. --- # 4. Export & Geography Mix ## A. Key Figures * **Export Mix:** **~50%** of total sales * **US Revenue:** **₹400 Cr** * **Tariff Benefit (US):** **₹50 Cr** expected post inventory transition ## B. US Market Dynamics * **Profitability Inflection:** US margins set to improve from Q1 FY27 as higher-duty inventory is cleared and reduced tariffs take effect. * **Aggressive Growth Targets:** Management expects US growth to significantly exceed low double-digit trends, with quarterly progress tracking. * **Export-Led Margin Strategy:** Company is actively scaling exports—currently half of sales—to drive margin expansion. ## C. Europe & Korea Growth * **Strategic Expansion Levers:** India-EU FTA and **Korea JV with Filmax** unlock near-term growth potential across Europe, US, and Korea. * **Korea Momentum:** Partnership expected to yield results within **12 months**, outpacing Japan’s longer development cycle. * **Japan: Long-Term Play:** Market entry remains phased and slow; success signals quality credibility but near-term impact limited. --- # 5. Product Mix & Innovation ## A. Key Figures * **Specialty Product Share:** **~70%** FY25 → **~50%** FY27 (temporary) → **target ~70%** post-FY27 * **Specialty & Semi-Specialty Mix Target:** **55%** current → **65% by 2027–28**, with **Q3 FY26 at 57%** * **Specialty Business CAGR:** **10%** over past six years * **BOPET Specialty Conversion:** **~20%** currently converted ## B. Specialty Product Share * **Temporary Dilution Expected:** Specialty share to decline to ~50% by FY27 due to ramp-up of new capacities, with clear roadmap to restore to ~70% within a couple of years post-FY27. * **Long-Term Upside:** Based on historical trends, company projects specialty share could reach **75% in four years**, indicating strong embedded growth potential. * **Progress Toward 2027–28 Goal:** Specialty and semi-specialty mix already improved to **57% in Q3 FY26**, ahead of 65% target, reflecting positive momentum. ## C. New Product Pipeline * **Growth Engine Intact:** Robust new product pipeline underpins sustained specialty expansion, supported by a proven **10% CAGR** over six years. * **BOPET Scaling Gaining Traction:** Initial delays in specialty conversion on BOPET line overcome; ~20% now converted with expectations of accelerated ramp-up and broader product offerings. ## D. House Brand Expansion * **Integrated Ecosystem Advantage:** Company leverages a **unique, full-cycle ecosystem**—spanning veterinary care, grooming, and post-op solutions—enhancing house brand relevance and customer stickiness. --- # 6. Risks & Trade Factors ## A. Key Figures * **BOPP Imports:** **3,000–4,000 tons/month**, primarily B/C-grade and non-domestic variants * **US Tariff P&L Impact:** **₹4–5 Cr** net impact in Q3 FY'26 (after ₹6 Cr in Q2 and ~₹8 Cr estimated) * **Anti-Dumping Duty P&L Impact:** **₹50 Cr** expected full-year impact on company’s profitability ## B. Import Competition * **Favorable BOPP Dynamics:** Import levels remain stable and non-disruptive, with demand-supply in equilibrium and **no significant Chinese BOPP inflows**, supporting pricing power. * **BOPET Supply Tightening:** Chinese BOPET production curbs—driven by government directives to cut unprofitable capacity—are corroborated by declining imports, aiding domestic pricing momentum. ## C. Tariff Exposure * **US Tariff Headwind Peaking:** Near-term financial impact from US tariffs largely realized in H1 FY'26, with potential for **incremental margin relief** if tariffs are reduced in coming periods. ## D. Anti-Dumping Risk * **BOPP Import Resilience:** Absence of anti-dumping duties on BOPP from China reflects India’s cost competitiveness in this segment, limiting near-term trade protection needs. * **BOPET Trade Action Pending:** Industry has filed anti-dumping petition against Chinese BOPET dumping; decision expected in **12–18 months**, leaving market exposed to surplus imports in the interim. --- # 7. Guidance & Outlook ## A. Key Figures * **Revenue Guidance:** **₹4,700–4,800 Cr** FY next ([~10% CAGR trajectory]) * **Debt Level:** **₹1,200 Cr** net debt as of Dec-25 ([15–18% annual reduction targeted]) * **Debt Reduction Target:** **₹200–250 Cr** annual reduction over next 2–3 years * **Margin Improvement:** **₹50 Cr** full-year improvement expected next fiscal ## B. Revenue Forecast * **Sustained Growth Trajectory:** Double-digit revenue growth expected in upcoming quarters, underpinned by higher utilization of recently expanded capacity and strong demand for specialty products. * **Capacity-Led Scaling:** Growth ambitions exceed 10% long-term, with available capacity providing headroom for accelerated top-line expansion across segments. * **Strategic Focus:** Emphasis on intrinsic value creation per business, with plans to unlock value opportunistically over time. ## C. Margin Improvement * **Recovery in Progress:** Q4 seasonality and non-recurrence of prior one-time charges (inventory loss, gratuity) to support margin rebound. * **Structural Tailwinds:** Margin expansion driven by higher specialty product mix, improved capacity utilization in film and other units, and export growth—though core film margins remain uncertain. * **Near-Term Confidence:** Next two quarters expected to deliver reasonably strong margins, with a **₹25/unit gross margin** as a strategic benchmark, though not formally guided. ## D. Debt Reduction Plan * **Aggressive Deleveraging Path:** Targeting **₹200–250 Cr** in annual net debt reduction over the next 2–3 years, supported by completed capex cycle and rising free cash flow. * **Capex Discipline:** No major capital outlays planned; future spending focused on value-added segments with high incremental ROCE potential. * **Break-Even Visibility:** Window films segment expected to reach break-even at **₹80–85 Cr** in sales, with **₹15 Cr** in marketing investment planned for next year.